Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls
    Published on 2025-03-18
    9 months ago
  • Correction: Neuropsychopharmacology Volume 50 Issue 1
    Published on 2025-03-18
    9 months ago
  • The role of sex in the association between cannabis use disorder and resting-state functional connectivity
    Published on 2025-03-17
    9 months ago
  • Rapid hippocampal synaptic potentiation induced by ketamine metabolite (2R,6R)-hydroxynorketamine persistently primes synaptic plasticity
    Published on 2025-03-16
    9 months ago
  • DRN-SNc serotonergic circuit drives stress-induced motor deficits and Parkinson’s disease vulnerability
    Published on 2025-03-16
    9 months ago
  • Lateral habenula induces cognitive and affective dysfunctions in mice with neuropathic pain via an indirect pathway to the ventral tegmental area
    Published on 2025-03-14
    9 months ago
  • Brain reactivity to nicotine cues mediates the link between resting-state connectivity and cue-induced craving in individuals who smoke or vape nicotine
    Published on 2025-03-12
    9 months ago
« Previous 1 … 27 28 29 30 31 … 143 Next »
Journal of Psychopharmacology
  • Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression
    Published on 2024-09-12
    1 year ago
  • Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers
    Published on 2024-09-12
    1 year ago
  • Blackcurrant (Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice
    Published on 2024-09-12
    1 year ago
  • Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis
    Published on 2024-09-12
    1 year ago
  • Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin
    Published on 2024-09-05
    1 year ago
  • Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?
    Published on 2024-09-02
    1 year ago
  • High-dose Vitamin-B6 reduces sensory over-responsivity
    Published on 2024-08-24
    1 year ago
« Previous 1 … 27 28 29 30 31 … 134 Next »
European Neuropsychopharmacology
  • Treatment or enhancement? The controversial role of medication in personality disorders
    Published on 2024-07-21
    1 year ago
  • Ensuring safety in cannabinoid prescriptions: A call for critical assessment
    Published on 2024-07-21
    1 year ago
  • Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition
    Published on 2024-07-18
    1 year ago
  • Childhood maltreatment: A call for a standardised definition and applied framework
    Published on 2024-07-18
    1 year ago
  • Deciphering the impact of metabolic anomalies in relation to severe mental illness
    Published on 2024-07-17
    1 year ago
  • Mixed features in mood episodes: Mismatch between intensity and valence in emotional responses
    Published on 2024-07-17
    1 year ago
  • Ketamine and new targets for treatment-resistant depression: A role for transforming growth factor-β1?
    Published on 2024-07-17
    1 year ago
« Previous 1 … 27 28 29 30 31 … 153 Next »

   Pharma Pub